
    
      Monocentre, open, non-placebo-controlled, single-group, single-dose study Safety measurements
      (12-lead ECG, vital signs, blood chemistry and haematology) will be conducted before and
      after the study, adverse events will be monitored throughout the study.

      Subjects should be hospitalized the day before the administration until 264 hours thereafter.
    
  